10nisman I’m going to half agree with you. I don’t believe UK approval is coming anytime soon and I believe most people here forget the expedited rolling review process (which they have a I’ll website page dedicated to) is completed in a 60+40 day process with stoppage of 30days if the UK requests further info by day 60. Humanigen is a tiny company in this landscape and will only provide marginal benefit to the pandemic if it were approved tomorrow.
That being said I’m invested here because I believe the risk adjusted value of the company is a bargain at anything below $15. The drug will eventually be approved and it will be bought up by some large pharma in the years coming. In terms of our COVID indication I don’t think any regulatory body is going to take the shot at HGEN without the NIH’s study results confirming our LIVE AIR results. HGEN simply does not have the lobbying power and infrastructure that BP has in place to get drugs through the approval process and considering this will be first time to market for Lenz regulators are going to take every precaution in approving the drug. I wouldn’t look at the SP much until 2Q22.
News 
Market Data 
Discover 
AI
